NCT05651594View on ClinicalTrials.gov

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Esophageal AdenocarcinomaLocally Advanced Gastroesophageal Junction AdenocarcinomaMetastatic Esophageal AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Esophageal AdenocarcinomaUnresectable Gastroesophageal Junction Adenocarcinoma
Interventions
PROCEDURE

Biopsy

Undergo tissue collection

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT scans

DRUG

Fluorouracil

Given IV

DRUG

Leucovorin

Given IV

DRUG

Oxaliplatin

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Propranolol Hydrochloride

Given PO

OTHER

Questionnaire Administration

Perceived Stress Scale

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Roswell Park Cancer Institute

OTHER